Radiopharmaceuticals, radioligand therapies (RLT) and theranostics are revolutionizing precision medicine by offering targeted diagnostic and therapeutic options that conventional drugs cannot match. By combining radioactive isotopes, for example 225Ac, 177Lu, 212Pb, with targeting molecules, these agents enable real-time disease visualization and precise radiation delivery to diseased cells, minimizing harm to healthy tissue. With growing applications in oncology, cardiology and neurology, radiopharmaceuticals are enhancing early detection and personalized treatment, empowering clinicians to make more informed decisions and supporting drug developers to bring innovative therapies to patients.
There are many considerations when developing a radiopharmaceutical, especially when you consider the complex interplay of biology, chemistry, nuclear physics and regulatory oversight. These agents must be precisely engineered to target specific tissues while carrying short-lived radioactive isotopes—placing stringent time constraints on their manufacturing, quality control and distribution.
At Labcorp, we speak radioactivity. With more than 40 years’ experience using radioisotopes and more than 10 years of radiopharmaceutical experience, we provide the insights and specialized global infrastructure required for safe handling of radioactive material according to regulatory standards.
Supported 18 preclinical biodistribution or Met ID studies in the past 2 years
Supported bioanalysis for ~20 radiopharmaceutical programs at our 5 global regulated LC-MS BioA sites over the past 3 years
Supporting 18 ongoing clinical trials, including radioactivity analysis for PK, near real-time analysis
Developing radiopharmaceuticals remains complex and resource-intensive. Consider Labcorp for a multidisciplinary approach, integrated development pathway and robust infrastructure to bring your life-changing radiopharmaceuticals from concept to clinic.
Preclinical
Bioanalytical Services
Clinical Trial Support
We specialize in radiopharmaceutical development solutions, helping your program to meet both time-sensitive delivery needs and stringent licensing requirements. For these studies, we can accommodate the need to process samples in very small numbers (as few as 1 sample at a time) as they are received from patients.
Radiopharmaceuticals are essential in oncology for precise diagnosis and targeted treatment. Through imaging techniques like PET and SPECT, they enable early tumor detection while delivering radiation directly to cancer cells to minimize damage to healthy tissue. This targeted approach enhances treatment effectiveness, reduces side effects and plays a key role in personalized cancer care.
To advance your radiopharmaceutical for cancer, trust in Labcorp for better, fast, more efficient development.
